{
  "docId": "019de072-468c-700c-89db-ca818deece7f",
  "docSlug": "40fd19b5105eee76fe8edee20250e12b",
  "documentTitle": "AN2 Therapeutics | IPO Presentation Deck | 27 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 11,
  "pageCount": 27,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Uses a Venn/concentric circle diagram to illustrate market segmentation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-468c-700c-89db-ca818deece7f/11",
  "deckHref": "/decks/019de072-468c-700c-89db-ca818deece7f",
  "deckJsonHref": "/decks/019de072-468c-700c-89db-ca818deece7f.json",
  "deckAnchorHref": "/decks/019de072-468c-700c-89db-ca818deece7f#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.35,
        "x": 0.6,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Concentric circles representing market segments",
      "attrs": null,
      "subkind": "venn",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19390bdb-7c88-45a6-b4ce-e237700f5851",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.3,
        "y": 0.38
      },
      "kind": "list",
      "text": "~44,000 Diagnosed with MAC lung disease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9530f839-186d-4be4-b195-126779358f2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.3,
        "y": 0.56
      },
      "kind": "list",
      "text": "~15,000 Diagnosed with treatment-refractory MAC lung disease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cac8ebbf-dd4d-4a61-9716-6e7eb64f5143",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.3,
        "y": 0.2
      },
      "kind": "list",
      "text": "~55,000 Diagnosed with NTM lung disease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffbf31c4-3f0e-40a3-9d51-ef13c01451a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.3,
        "y": 0.05
      },
      "kind": "metric",
      "text": "~200,000 estimated patients with NTM lung disease in U.S.",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b3b966a-c478-4b2d-b71f-f4e1b9838479",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.3,
        "y": 0.68
      },
      "kind": "paragraph",
      "text": "*Treatment-refractory = Patients that remain culture positive despite ≥6 months of guideline-based antibiotic therapy",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4aa3775d-d9e7-48d0-bdca-101076e63598",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.3,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1. Internal analysis, AN2 Therapeutics, Inc. 2. Strollo SE, et al. Ann Am Thorac Soc. 2015;12(10):1458-1464",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "148c98ea-79aa-4dcd-9233-8ca369a038b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "title",
      "text": "Initial indication targeting treatment-refractory MAC lung disease",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e608bad-7aa0-4f9f-9227-69b95799bb16",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "NTM lung disease underserved and growing market opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "384fb898-a624-455c-ac4e-2402741984a2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "40122046-6af8-435c-bcd1-932f1425f3f1",
      "evidence": "Funnel-like breakdown of total addressable market into specific target segment",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 10,
      "beatId": "15046727-6f68-47c4-9a45-b89d72c286c9",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slides 10-12 describe the problem of NTM lung disease",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 11,
      "from": 11,
      "beatId": "411cb3f4-d879-4121-a8e7-9b3252458882",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "Slide 11 provides market sizing information",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4aa0dbf2-56da-494f-901a-64b26c295698",
      "evidence": "Slides 10-12 emphasize the unmet medical need",
      "position": 0,
      "objective": "Highlight the need for new treatments for NTM lung disease",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 27,
      "from": 1,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "5c43fe0e-f0f3-4ff4-8709-c2c99c61b351",
      "evidence": "The deck starts and ends with the company's mission",
      "position": 1,
      "objective": "Present a clear mission and vision for AN2 Therapeutics",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}